STOCK TITAN
  1. Home
  2. News
  3. BBLG

Bone Biologics Corp - BBLG STOCK NEWS

Welcome to our dedicated news page for Bone Biologics (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bone Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bone Biologics's position in the market.

News
Bone Biologics Announces Closing of $2.0 Million Public Offering
Rhea-AI Summary
Bone Biologics Corporation (BBLG) closes public offering, raising $2.0 million for clinical trials and patent portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
offering
-
News
Bone Biologics Announces Pricing of $2.0 Million Public Offering
Rhea-AI Summary
Bone Biologics Corporation (BBLG) announces the pricing of a public offering of 781,251 shares of common stock and warrants at $2.56 per share, aiming to raise capital for its orthobiologic products in spine fusion markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
offering
-
News
Bone Biologics Reports Progress With NB1 Clinical Program
Rhea-AI Summary
Bone Biologics Corporation (BBLG) progresses with human clinical testing for spinal fusion product candidate NB1, with three hospital sites engaged in the pilot trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
News
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
Rhea-AI Summary
Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) appoints Robert E. Gagnon, a seasoned finance and business operations professional, to its board of directors. With over 20 years of experience in leading global finance operations and serving in executive roles at various life sciences companies, Mr. Gagnon's appointment is expected to bring valuable expertise in clinical stage companies, capital raising, and commercial organizations to support Bone Biologics' growth and its pilot study with NB-1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
management
-
News
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Rhea-AI Summary
Bone Biologics Corporation (BBLG) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The company's common stock will continue to be listed on The Nasdaq Capital Market, but will remain under Nasdaq’s discretionary panel monitor until June 28, 2024. Bone Biologics failed to meet the closing bid price of $1.00 for 30 consecutive business days but regained compliance by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, as of January 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
-
News
Bone Biologics Announces 1-for-8 Reverse Stock Split
Rhea-AI Summary
Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) announces a planned 1-for-8 reverse stock split of its shares of common stock, effective December 20, 2023. Stockholders approved the split at a special meeting on December 12, 2023. The reverse stock split aims to adjust the stock price and number of outstanding shares, with the new CUSIP number of the common stock being 098070501.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
none
News
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Bone Biologics Corporation (NASDAQ: BBLG) announced the closing of a registered direct offering and a concurrent private placement, raising approximately $729,000. The company sold 1,139,063 shares of common stock at a purchase price of $0.64 per share and issued unregistered warrants to purchase up to an aggregate of 1,139,063 shares of its common stock. The gross proceeds will be used for clinical trials, maintaining and extending its patent portfolio, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
offering
-
News
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Bone Biologics Corporation (NASDAQ: BBLG) Announces Registered Direct Offering and Private Placement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.79%
Tags
offering
-
News
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
Rhea-AI Summary
Bone Biologics provides update on clinical development initiatives for its NB1 bone graft device, expects to start pilot study before the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
News
Bone Biologics Prices $5.0 Million Underwritten Public Offering
Rhea-AI Summary
Bone Biologics announces pricing of underwritten public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-58.27%
Tags
offering
Stock BBLG logo
Bone Biologics Corp

Nasdaq:BBLG

BBLG Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BBLG Stock Data

1.54M
480.93k
8.15%
1.26%
1.72%
Surgical Appliance and Supplies Manufacturing
Manufacturing
Link
United States
Burlington

About BBLG

a publicly-held biotechnology company that is a spin off of the musculoskeletal transplant foundation (mtf) using technology discovered and licensed from ucla. bone biologics market and focus is in the regenerative medicine orthobiologics space. bone biologics was founded in 2004 by university of california professors in collaboration with an osaka university professor and a usc surgeon and acquired in 2006 by mtf as the major shareholder, who has been the primary funder since the acquisition. the company’s proprietary, patented platform technology ucb-1™, exclusively licensed from ucla, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and rhesus monkey) studies that have demonstrated that the ucb-1™ technology facilitates superior normal bone growth. the company believes that as a platform technology, ucb-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.